74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Optinose Inc
Closed
Sector Healthcare
5.65 -4.07
Overview
Share price change
24h
Min
5.65
Max
5.69
Income | 8M 393K |
|---|---|
Sales | -53K 20M |
EPS | 0.002 |
Profit margin | 1.923 |
Employees | 132 |
EBITDA | 8.4M 5.8M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +203.29 upside |
Next Earnings | 6 Mar 2025 |
|---|
Market Cap | 60M |
|---|---|
Previous open | 9.72 |
Previous close | 5.65 |
News Sentiment
By Acuity
34%
66%
92 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Optinose Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Optinose Inc Forecast
Price Target
By TipRanks
203.29% upside
12 Months Forecast
Average 17.5 USD 203.29%
High 18 USD
Low 17 USD
Based on 2 Wall Street analysts offering 12 month price targets forOptinose Inc - Dist in the last 3 months.
Sentiment
By Acuity
92 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Optinose Inc
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
